Why Pharvaris N.V.’s (PHVS) Stock Is Up 5.21%
As of Thursday, June 25, Pharvaris N.V.’s PHVS share price has surged by 5.21%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Commentary & Analysis
Why Pharvaris N.V.’s (PHVS) Stock Is Up 6.36%
As of Wednesday, June 17, Pharvaris N.V.’s PHVS share price has surged by 6.36%, which has investors questioning if this is right time to sell.Michael Rose
Why Pharvaris N.V.’s (PHVS) Stock Is Up 5.46%
As of Wednesday, April 29, Pharvaris N.V.’s PHVS share price has surged by 5.46%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Pharvaris N.V.’s (PHVS) Stock Is Down 5.16%
As of Thursday, April 02, Pharvaris N.V.’s PHVS share price has dipped by 5.16%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Pharvaris N.V.’s (PHVS) Stock Is Down 6.68%
As of Tuesday, March 03, Pharvaris N.V.’s PHVS share price has dipped by 6.68%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | PHVS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,364.0 | $569.9 | 56% |
|
| Shares Out (Mil) | 76.5 | 44.8 | 57% |
|
| Institutional Ownership | 95.2% | 84.6% | 67% |
|
| Float (Mil) | 42.4 | 45.1 | 44% |
|
| Beta | -2.33 | 0.67 | 0% |
|
| Avg Daily Volume (000s) | 298 | 294 | 51% |
|
| Price Change (52-week) |
72.5% | 65.2% | 87% |
|
| Growth | PHVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (45.3%) | (2.0%) | 8% |
|
| EPS (5yr) | 11.9% | 14.9% | 50 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (58.9%) | (14.9%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 13 | 13 | |
| Current EPS | ($0.753) | ($3.047) | ($2.809) | |
| Month Ago EPS | ($0.744) | ($2.978) | ($2.669) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.857) | ($3.381) | ($3.063) | |
| Year/Year Chg | (10.7%) | (12.6%) | (71.7%) | |
| Financials | PHVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $230 | na |
|
| Net Income (TTM) (Mil) | ($206) | ($11) | 6% |
|
| EPS (TTM) | ($3.487) | ($0.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($161) | ($6) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $17 | $4 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $7 | 16% |
|
| Enterprise Value (Q1) (Mil) | $1,461 | $493 | 46% |
|
| Valuation | PHVS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.93 | 2.89 | 84% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PHVS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | (0.2%) | na |
|
| ROA | (62.9%) | (25.5%) | 9% |
|
| ROE | (69.3%) | (21.4%) | 12% |
|
| Liabilities to Assets | 10.0% | 35.5% | 5% |
|
| F-Score | 1 | 3 | 1% |
|
Pharvaris N.V. did not pass any screens on 7/30/2026.
